Maintenance or eradication of residual disease in indolent lymphoma: Where do we stand?

Journal of Clinical Oncology

Volumn 27, Issue 10, 2009, Pages 1540-1542

  Hagenbeek, Anton ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; INTERFERON; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; EDITORIAL; ERADICATION THERAPY; FOLLICULAR LYMPHOMA; GRAFT VERSUS LYMPHOMA EFFECT; HIGH RISK PATIENT; HUMAN; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA; NEOPLASM, RESIDUAL;

EID: 63749107163     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.8457     Document Type: Editorial

References (17)

1. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:84478452, 2005
2. Tan D, Rosenberg SA, Levy R, et al: Survival in follicular lymphoma: The Stanford experience, 1960-2003. Blood 110, 2007 (abstr 3428)
3. Khouri IF, McLaughlin P, Saliba RM, et al: Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after non- myeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111:5530-5536, 2008
4. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitox- antrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007
5. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 112:4824-4831, 2008
6. Hiddemann W, Kneba M, Dreyling M, et al: Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincris- tine and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
7. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:45794586, 2008
8. Ezdinli EZ, Harrington DP, Kucuk O, et al: The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. Cancer 60:156-160, 1987
9. Steward WP, Crowther D, McWilliam LJ, et al: Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 61:441-447, 1988
10. Rohatiner AZ, Gregory WM, Peterson B, et al: Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215-2223, 2005
11. Hochster H, Weller E, Gascoyne RD, et al: Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG 1496 study. J Clin Oncol 27:1607-1614, 2009
12. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event free survival and response duration compared with the standard weekly x× 4 schedule. Blood 103:4416-4423, 2004
13. Hainsworth JD, Litchy S, Shaffer DW, et al: Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-A randomized phase II trial of the Minnie Pearl Cancer Res Network. J Clin Oncol 23:1088-1095, 2005
14. van Oers MHJ, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lym- phoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006
15. Gordan LN, Grow WB, Pusateri A, et al: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23:1096-1102, 2005
16. 90Y-ibritumomab tiuxetan after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008
17. Oers MHJ, van Glabbeke M, Baila L, et al: Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized Intergroup study. Blood 112, 2008 (abstr 836)